Clinical studyEmbolization Efficacy and Treatment Effectiveness of Transarterial Therapy for Unresectable Hepatocellular Carcinoma: A Case-Controlled Comparison of Transarterial Ethanol Ablation with Lipiodol–Ethanol Mixture versus Transcatheter Arterial Chemoembolization
Section snippets
Study Design
The present study was a case-controlled study of 60 patients with unresectable HCC treated with transarterial therapy. A group of 30 patients who received Lipiodol–ethanol treatment between March and December 2002 was compared with a group of 30 patients who received chemoembolization in 2005. Institutional review board approval was obtained for phase I and II studies of Lipiodol–ethanol treatment, as well as for the comparative study of Lipiodol–ethanol treatment versus chemoembolization. The
Results
When comparing Lipiodol–ethanol versus chemoembolization, the degree of Lipiodol retention in tumor at 2 months was significantly higher in the Lipiodol–ethanol group than in the chemoembolization group (89.5% ± 10.7% vs 47.5% ± 21.2%; P < .0001; Table 1). Tumor response to treatment at 1 year or less—expressed in a ratio of patients showing partial response versus static disease versus lesion size progression—were 18/12/0 in the Lipiodol–ethanol group and 12/13/5 in the chemoembolization
Discussion
The goals of chemoembolization are to deliver a highly concentrated dose of chemotherapy to tumor cells, to prolong the contact time between the chemotherapeutic agents and the tumor cells, and to minimize systemic toxicity from the chemotherapeutic agents (16). Lipiodol is a key ingredient in the treatment protocol of chemoembolization, as it serves the functions of a drug-carrying, tumor-seeking, and embolizing agent. The deliverable chemoembolization agent is prepared in the form of an
References (34)
- et al.
Arterial embolisation or chemoembolization vs symptomatic treatment in patients with unresectable HCC: a randomised controlled trial
Lancet
(2002) - et al.
Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable HCC
Hepatology
(2002) - et al.
Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma
J Vasc Interv Radiol
(2008) - et al.
Superselective transcatheter arterial embolization with ethanol and iodized oil for hepatocellular carcinoma
J Vasc Interv Radiol
(1993) - et al.
Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol-ethanol mixture: phase II study
J Vasc Interv Radiol
(2008) - et al.
Chemoembolization of hepatocellular carcinoma
J Vasc Interv Radiol
(2002) - et al.
Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions
J Biol Chem
(2001) - et al.
Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and Gelfoam
Clin Radiol
(1993) - et al.
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
J Hepatol
(2003) - et al.
Rising incidence of hepatocellular carcinoma in the United States
N Engl J Med
(1999)
Increased mortality from liver cancer in England and Wales is not related to hepatitis C (letter)
Br Med J
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy and survival
Radiology
Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization
Radiology
Intra-arterial alcoholization of advanced hepatocellular carcinoma
Cancer Chemother Pharmacol
Peribiliary plexa—important pathways for shunting of iodized oil and silicon rubber solution from the hepatic artery to the portal vein: an experimental study in rats
Invest Radiol
Transcatheter liver lobar ablation: an experimental trial in an animal model
Eur Radiol
Efficacy and safety of preoperative lobar or segmental ablation via transarterial administration of Ethiodol and ethanol mixture for treatment of hepatocellular carcinoma: clinical study
World J Surg
Cited by (34)
Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer
2020, Translational OncologyCitation Excerpt :This trend was more apparent in HCC. Several retrospective studies have reported on the relationship between Lipiodol deposition and longer survival [19,28–33], and some authors reported an association between complete Lipiodol tumor coverage with a lower local tumor recurrence rate [34]. The imaging follow-up period in our study was relatively short, and the trial design did not include time-to-tumor progression as an endpoint.
Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma
2018, Hepatobiliary and Pancreatic Diseases InternationalCitation Excerpt :Adjuvant TACE was performed at 4–6 weeks after hepatectomy by experienced interventional radiologist. Selective catheterization of the hepatic artery branches to the remnant liver was achieved with a 5-F catheter or microcatheter [8]. Lipidol-cisplatin emulsion containing 10–30 mg cisplatin and 5–10 mL lipiodol was prepared for intra-arterial infusion.
Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes
2016, Journal of Vascular and Interventional RadiologyCitation Excerpt :Second, although the inclusion of patients with different tumor stages and liver function status could be considered a limitation, it provided an opportunity for comprehensive analysis of the tumor and liver factors affecting treatment outcome. To achieve this purpose, we included the entire patient cohort treated with TEA in our institution, including data of patients that had been reported previously (1–3). Third, the use of CT instead of MR imaging was less desirable in the assessment of tumor response.
Diffusion-weighted magnetic resonance imaging to evaluate microvascular density after transarterial embolization ablation in a rabbit VX2 liver tumor model
2014, Magnetic Resonance ImagingCitation Excerpt :Currently, transarterial embolization ablation (TEA) is the preferred method for nonsurgical removal of HCC, but the long-term efficacy is not ideal. Infusions of iodized oil and ethanol mixtures via the hepatic artery have improved the efficacy of TEA [10,11]. The rabbit VX2 tumor model is a valuable animal model because tumors are easily implanted and grow quickly [12].
Comparison of Survival Outcomes in Transarterial Ethanol Ablation and Liver Resection for Solitary Hepatocellular Carcinoma ≤ 5 cm in Patients Stratified by Liver Function
2022, CardioVascular and Interventional Radiology
None of the authors have identified a conflict of interest.